Management of intracerebral hemorrhage – Use of statins

Edward Van Matre, Deb S. Sherman, Tyree H. Kiser

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalVascular health and risk management
Volume12
DOIs
StatePublished - Apr 18 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cerebral Hemorrhage
Nervous System Trauma
Therapeutics
Primary Prevention
Secondary Prevention
LDL Cholesterol
Stroke
Clinical Trials
Morbidity

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Management of intracerebral hemorrhage – Use of statins. / Van Matre, Edward; Sherman, Deb S.; Kiser, Tyree H.

In: Vascular health and risk management, Vol. 12, 18.04.2016, p. 153-161.

Research output: Contribution to journalReview article

Van Matre, Edward ; Sherman, Deb S. ; Kiser, Tyree H. / Management of intracerebral hemorrhage – Use of statins. In: Vascular health and risk management. 2016 ; Vol. 12. pp. 153-161.
@article{389e6ab68e074901b76d0309a794ca89,
title = "Management of intracerebral hemorrhage – Use of statins",
abstract = "Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.",
author = "{Van Matre}, Edward and Sherman, {Deb S.} and Kiser, {Tyree H.}",
year = "2016",
month = "4",
day = "18",
doi = "10.2147/VHRM.S75399",
language = "English (US)",
volume = "12",
pages = "153--161",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Management of intracerebral hemorrhage – Use of statins

AU - Van Matre, Edward

AU - Sherman, Deb S.

AU - Kiser, Tyree H.

PY - 2016/4/18

Y1 - 2016/4/18

N2 - Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.

AB - Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.

UR - http://www.scopus.com/inward/record.url?scp=84964454345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964454345&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S75399

DO - 10.2147/VHRM.S75399

M3 - Review article

VL - 12

SP - 153

EP - 161

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -